Dear Reader,
As we reach the final issue of Drugs—Real World Outcomes for 2019, we wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content.
2019 was a successful year for Drugs—Real World Outcomes. Over 20 articles have been published; the most popular of these, in terms of downloads from SpringerLink, have been:
Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study. Oshikoya, K.A., Carroll, R., Aka, I. et al. Drugs—Real World Outcomes (2019) 6: 59. https://doi.org/10.1007/s40801-019-0151-7
Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services. Hendrix, I., Page, A.T., Korhonen, M.J. et al. Drugs—Real World Outcomes (2019) 6: 105. https://doi.org/10.1007/s40801-019-0157-1
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study. Sakata, Y., Matsuoka, T., Ohashi, S. et al. Drugs—Real World Outcomes (2019) 6: 27. https://doi.org/10.1007/s40801-019-0150-8
Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review. Joshi, R., Latremouille-Viau, D., Meiselbach, M.K. et al. Drugs—Real World Outcomes (2019) 6: 1. https://doi.org/10.1007/s40801-018-0146-9
A Benefit Risk Review of Pediatric Use of Hydrocodone/Chlorpheniramine, a Prescription Opioid Antitussive Agent for the Treatment of Cough. Sloan, V.S., Jones, A., Maduka, C. et al. Drugs—Real World Outcomes (2019) 6: 47. https://doi.org/10.1007/s40801-019-0152-6
Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016. Azekour, K., Belamalem, S., Soulaymani, A. et al. Drugs—Real World Outcomes (2019) 6: 11. https://doi.org/10.1007/s40801-019-0148-2
Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study. Lin, HM.D., Lai, CL., Dong, YH. et al. Drugs—Real World Outcomes (2019) 6: 93. https://doi.org/10.1007/s40801-019-0156-2
PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice. Parhofer, K.G., von Stritzky, B., Pietschmann, N. et al. Drugs—Real World Outcomes (2019) 6: 115. https://doi.org/10.1007/s40801-019-0158-0
We thank the authors who have contributed articles to Drugs—Real World Outcomes over the course of 2019. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for Drugs—Real World Outcomes in the last 12 months:
Anabela Barcelos, Portugal
Francisco Batel-Marques, Portugal
Marc Buyse, Belgium
Pia Caduff-Janosa, Sweden
Camilla Callegari, Italy
Antonio Clavenna, Italy
Jacqueline Corrigan-Curay, USA
Benjamin Daniels, Australia
Roni P. Dodiuk-Gad, Israel
Khalid Eljaaly, Saudi Arabia
Andrea Fagiolini, Italy
Filipa Farinha, UK
Nicola Ferri, Italy
Daniel Fife, USA
Meghan Gabriel, USA
Armando Gonzalez-Ruiz, UK
Kaushik Guha, UK
Jan Hasselstrom, Sweden
Benjamin Hohlfelder, USA
Laurence G. Howes, Australia
Magnus Ingelman-Sundberg, Sweden
Aditi Kadakia, USA
Emily Karanges, Australia
Abhishek Kavati, USA
Farzin Khosrow-Khavar, Canada
Shunsuke Kiuchi, Japan
Roger Knaggs, UK
Eitaro Kodani, Japan
Georgios D. Kotzalidis, Italy
Gilles Lambert, France
Kathryn Lang, USA
Marie Linder, Sweden
Jette Möller, Sweden
Lubov Matchekhina, Russia
Dídac Mauricio, Spain
Omid Mehrpour, Iran
Jose J. Mira, Spain
Pablo Mora, USA
Takatoshi Nawa, Japan
Khac-Dung Nguyen, France
Alexandra C. Pacurariu, The Netherlands
Vidhya Parameswaran, Canada
Klaus G. Parhofer, Germany
Wolfgang Philipp-Dormston, Germany
Sonam Puri, USA
Dima M. Qato, USA
Concetta Rafaniello, Italy
Lorenza Rimassa, Italy
Julie Rouette, Canada
Rafael Santana-Davila, USA
John D. Seeger, USA
Darshini Shah, USA
Michael D. Shapiro, USA
Caroline Sirois, Canada
Giuseppe Sito, Italy
Liberata Sportiello, Italy
Hema Sundaram, USA
Wade Thompson, Denmark
Sermin Toto, Germany
Joachim Veith, USA
Sigurd Vitols, Sweden
Kristie R. Weir, Australia
Dahlia Weitzman, Israel
Mike Wilcock, UK
Richard Willke, USA
Antoinette Wozniak, USA
Srikanth Yandrapalli, USA
Shan Yin, USA
Kazuki Yoshida, USA
Ulrich M. Zanger, Germany
In addition, we would like to thank the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:
G.C. Alexander, Johns Hopkins University, Baltimore, MD, USA
A. Beresniak, Data Mining International, Geneva, Switzerland
H. Birnbaum, Analysis Group, Inc., Boston, MA, USA
J. Bottomley, Amygdala Ltd., Letchworth Garden City, England
P. Denig, University of Groningen, Groningen, The Netherlands
J.E. Fincham, Presbyterian College School of Pharmacy, Clinton, SC, USA
B. Godman, Karolinska Institutet, Stockholm, Sweden
D. Goldsmith, Goldsmith Pharmacovigilance and Systems, New York, NY, USA
S. Karve, AbbVie, Chicago, IL, USA
C. Kozma, CK Consulting Associates, St. Helena Island, SC, USA
T. Lasky, U.S. Food and Drug Administration, Silver Spring, MD, USA
A.A. Mangoni, Flinders University, Adelaide, SA, Australia
S. Mimica-Matanovic, University Hospital Osijek, Osijek, Croatia
P.G. Parmar, Auckland University of Technology, Auckland, New Zealand
B. Rinaldi, University of Capania Luigi Vanvitelli, Naples, Italy
J.K. Sluggett, Monash University, Parkville, VIC, Australia
K.A. Swanson, University of Oklahoma, Oklahoma City, OK, USA
F. van Hunsel, The Netherlands Pharmacovigilance Centre Lareb, Brabant, The Netherlands
J.E Ware Jr., John Ware Research Group Incorporated, Watertown, MA, USA
Q. Zou, Medstar Health Research Institute, Washington, DC, USA
We do hope that you have found the articles published throughout the year in Drugs—Real World Outcomes to be interesting and informative. The editorial schedule for 2020 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.
With best wishes
Dene Peters (Editor) and Kathy Fraser (Deputy Editor)
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Acknowledgement to Referees. Drugs - Real World Outcomes 6, 151–153 (2019). https://doi.org/10.1007/s40801-019-00170-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40801-019-00170-x